Showing results (121-130 of 162) with videos related to

Sort By:
Pageof 17
BMC Cancer|July 6, 2010
Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancerEmiliano Cocco, Francesca Casagrande, Stefania Bellone, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|February 12, 2015
Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitroLiancheng Zhu, Salvatore Lopez, Stefania Bellone, et al.
Gynecologic Oncology|July 1, 2020
Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinomaElena Bonazzoli, Stefania Bellone, Luca Zammataro, et al.
Scientific Reports|January 24, 2020
Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecanBurak Zeybek, Aranzazu Manzano, Anna Bianchi, et al.
Frontiers in Oncology|March 3, 2020
Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian CancerEmanuele Perrone, Salvatore Lopez, Burak Zeybek, et al.
Molecular Oncology|January 1, 2020
Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivoEmanuele Perrone, Paola Manara, Salvatore Lopez, et al.
British Journal of Cancer|June 29, 2016
Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivoEmiliano Cocco, Salvatore Lopez, Jonathan Black, et al.
Gynecologic Oncology|January 27, 2023
The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivoChanhee Han, Blair McNamara, Stefania Bellone, et al.
Gynecologic Oncology|July 15, 2017
Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expressionGulden Menderes, Elena Bonazzoli, Stefania Bellone, et al.
Gynecologic Oncology|May 31, 2022
Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neuGhanshyam Yadav, Dana M Roque, Stefania Bellone, et al.
Pageof 17